K etamine, a noncompetitive N-methyl-d-aspartate receptor antagonist, has been administered neuraxially for the treatment of postoperative pain, chronic cancer pain, and neuropathic pain, respectively. 1,2 Although ketamine was shown to induce neurotoxicity when administered intrathecally in animals and patients, 3, 4 there is considerable uncertainty about the possible toxicity of ketamine when administered next to neuronal structures. In the past, local neurotoxicity of ketamine was attributed to added preservatives. 5, 6 Malinovsky et al. demonstrated in rabbits that only animals receiving chlorobutanol (with or without ketamine) developed signs of neurological damage, but not the ones receiving pure ketamine. 5 Similarly, Errando et al. showed in pigs that ketamine alone induced no neuronal damage, whereas ketamine with benzethonium induced discrete neurotoxic effects. 6 Surprisingly, benzethonium alone displayed even greater toxicity than did the combination of benzethonium with ketamine. Benzethonium itself induces apoptosis in a variety of human epithelial tumors as well as embryonic fibroblasts and has been advocated as an agent with significant broadspectrum anticancer activity. 7 Recently, we demonstrated in human neuroblastoma and T-lymphoma (Jurkat) cells that the preservative-free ketamine racemate as well as the S(ϩ)-enantiomer induce apoptosis in millimolar concentrations via the mitochondrial pathway presumably unrelated to N-methyl-d-aspartate signaling. 8 Unfortunately, commercially available preservative-free S(ϩ)-ketamine should not be stored at room temperature for longer than 12 hours, which makes administration for a longer time period rather difficult. Although benzethonium-containing ketamine has been administered epidurally without signs of neurologic injury, 9 it would be interesting to know whether its toxicity has a synergetic effect.
Therefore, we determined the percentage of apoptotic and necrotic cells induced by S(ϩ)-ketamine, benzethonium, the commercially available combination of both (Ketanest S, Pfizer, Berlin, Germany), and the combination of the pure substances in human cells of hematogenic and neuronal origin. Subsequently, we tested the synergism of both substances in neuronal cells and primary astrocytes.
METHODS

Cell Cultures
The origin and characteristics of human Jurkat Tlymphoma cells and human neuroblastoma cells have been described. 10 -12 Memorial Institute (RPMI) 1640 medium (supplemented with 10% heat-inactivated fetal calf serum, 2 mM l-glutamine, and 50 U/mL of penicillin and 50 g of streptomycin) was used as the suspension medium in both cell lines. Culture condition for all cells was a humidified atmosphere containing 5% carbon dioxide at 37°C. Cultures of primary rat astrocytes were prepared from cerebral cortices of P2 Wistar rats. After approval of the local Animal Research Committee, rats were anesthetized using Forene (Abbott, Abbott Park, Illinois), decapitated, and the brains quickly removed. To avoid fibroblast or endothelial contamination, cortical tissue was carefully isolated from blood vessels and meninges, rinsed with Dulbecco's modified Eagle medium (DMEM, Invitrogen, Carlsbad, California), dissociated by trypsinization, and suspended in DMEM supplemented with 10% fetal bovine serum (Invitrogen), penicillin (80 U/mL), and streptomycin (0.2 mg/mL). Dissociated cells were plated in 75-cm 2 culture flasks (Corning Incorporated Life Sciences, Lowell, Massachusetts). After 5 days, cultures were washed with DMEM to remove cellular debris and maintained until subconfluency. Cellular debris, microglia, oligodendrocytes, and their early precursor cells were then removed by shaking flasks overnight at 250 revolutions per minute (rpm) at 37°C. The resulting cell population consisted of Ͼ98% primary rat astrocytes, as determined by immunocytochemical analysis using antibodies against glial fibrillary acidic protein (Chemicon International, Temecula, California). For all following experiments, cells were trypsinated and replated on 6-well cell culture plates coated with poly-d-lysine (0.1 mg/mL).
Exposure of Cells to Benzenthonium Chloride and S(؉)-Ketamine
Cells were treated for 24 hours at 37°C with medium alone as negative control, or indicated concentrations of S(ϩ)ketamine, benzethonium alone, S(ϩ)-ketamine, and benzethonium chloride or Ketanest S (Pfizer, Berlin, Germany) diluted in cell culture medium.
Flowcytometric Analysis
For evaluation of cytotoxic effects, cells were stained after complete incubation before flowcytometric analysis. The principle of double staining with annexin-V and 7-aminoactinomycin D (7AAD) has been described. 11, 12 In brief, staining of cells with annexin-V and 7AAD allows distinguishing between the fraction of cells in an early phase of apoptosis and those already in a late apoptotic or necrotic state. Cells staining positive only for annexin-V but not for 7AAD are defined as early apoptotic, whereas detection of 7AAD staining indicates late apoptosis or necrosis in stained cells. The sum of both fractions indicates the percentage of overall cell death.
For staining and flowcytometric analysis, cells were washed twice with cold phosphate buffered saline. Adherent SHEP neuroblastoma cells were first detached with trypsin/EDTA 0.05% for 3 minutes at 37°C and resuspended at a concentration of 1 ϫ 10 6 cells/mL in annexin-V binding buffer (10 mM N-[2-hydroxyethyl] piperazin-n ϭ Ϫ3[propansulfonic acid]/NaOH, pH 7.4, 140 mM NaCl, 2.5 mM CaCl 2 ). After incubating the cells 15 minutes at room temperature with 5 L annexin-V and 5 L 7AAD (5 g/mL), we started measuring with a FACScalibur (Becton Dickinson, Heidelberg, Germany) using CellQuest Pro software. Every measurement included 10,000 cells.
Detection of Mitochondrial Metabolic Activity
For in vitro determination of mitochondrial viability we used the tetrazolium hydroxide (XTT) assay. XTT, a yellow tetrazolium salt, Is cleaved to a soluble orange formazan dye, which can be measured by absorbance. To measure cell viability using XTT, samples were prepared with 100 L of cell suspension in 96-well cell culture plates and cells were allowed to adhere overnight. Neuroblastoma cells were incubated in a density of 20,000 cells/Well, while primary rat astrocytes were adjusted to 100,000 cells/Well according to their lower metabolic rate. Subsequent to incubation time, 50 L of XTT assay solution (XTT 1 mg/mL and phenazine methosulfate 50 M diluted in cell culture medium) was added to each well. Mixing the samples gently for 1 min was followed by incubation for 120 min at 37°C. After additional mixing for 3 min the absorbance was measured spectrophotometrically at a wavelength of 450 nm.
Statistical Analysis
Each experiment was performed 3-fold. Results are expressed as mean Ϯ sd. Comparisons between groups were made with Student's t test using the SPSS program version 18.0 (SPSS Inc., Chicago, Illinois). P Ͻ 0.05 was considered significant. The calculations of concentration-response relationships and LD 50 values were performed with nonlinear regression analysis using the Graph Pad Prism Software version 5.0 (GraphPad Software Inc., La Jolla, California) with the log(inhibitor) versus response mode assuming variable slopes. Resulting equations in the form of [response ϭ bottom value ϩ (top value Ϫ bottom value)/(1 ϩ 10ˆ((LogLD 50 -concentration) *HillSlope))] were used to draw concentration-response slopes and the isobole (Ϯconfidence interval 95%) for benzethonium, S(ϩ)-ketamine, and the equitoxic combination of both drugs. An isobologram is a commonly used method to assess combined drug effects. Therefore, a graph of equally effective dose pairs (isoboles) for a single effect level is drawn. A particular effect level is selected, such as 50% of the maximum (LD50) and concentrations of drug A and drug B (each alone) that give this effect are plotted as axial points in a Cartesian plot. This graph represents the locus of points (concentration pairs) that lead to a simply additive effect. Experimentally observed concentration pairs that produce this specific effect level can be compared with the line of additivity to discriminate between subadditive, additive, and superadditive effects. 13 
RESULTS
In Jurkat T-lymphoma cells, S(ϩ)-ketamine (2 mM) and the preservative benzethonium (5 M) induced 31.8 Ϯ 6.2% and 32.3 Ϯ 5.5% cell death, respectively (Fig. 1A) . Addition of benzethonium to the preservative-free S(ϩ)-ketamine and the commercially available mixture Ketamine S increased the toxicity to almost 3-fold (86.3 Ϯ 1.9% and 80.8 Ϯ 6.7%, respectively). All treatments increased the percentage of apoptotic cells.
In neuroblastoma cells the concentrations of all solutions were chosen in the linear part of the concentration-effect curve. In this setting, benzethonium alone did not lead to an increased percentage of cell death in human neuroblastoma cells, whereas coadministration of benzethonium to S(ϩ)-ketamine (4 mM) increased its toxicity significantly from 63.7 Ϯ 1.4% to 84.4 Ϯ 6.6% (Fig. 1B) . Again, a mixture of benzethonium with S(ϩ)-ketamine and the commercially available mixture (Ketanest S) induced the same amount of apoptosis and cell death (Fig. 1B) .
To discriminate the ability of benzethonium and S(ϩ)ketamine to have a subadditive, additive, or superadditive toxic effect, we first investigated the dose-response relationship and the calculated LD50 of these substances in human neuroblastoma (SHEP) cells and primary rat astrocytes using the XTT assay. The dose-response curves (Fig.  2) based on increasing doses of S(ϩ)-ketamine and benzethonium allowed us to calculate the LD50. Subsequently, an isobologram was established to compare the calculated additive effect with the observed effect of the drug combination. The LD50 of S(ϩ)-ketamine was 4.0 mM in human neuroblastoma (SHEP) cells and 4.7 mM in primary rat astrocyte. The LD50 of benzethonium was 10.2 M in human neuroblastoma (SHEP) cells and 9.5 M in primary rat astrocytes, showing the differential sensitivity of different cell lines to the LD50 of these substances. To evaluate the LD50 of the combined substances, we exposed the cells to increasing fractions (20%-80%) of the LD50 of both substances in combination (Fig. 3) . The results were used to calculate the combined LD. The combined LD50 was applied to an isobologram of each cell line (Fig. 4) . The combined LD50 was within the borders of the 95% confidence interval of the corresponding isobol, indicating an additive effect in both cell lines.
DISCUSSION
Although preservatives added to ketamine have often been thought to induce neurotoxicity, we showed that the toxic effects of S(ϩ)-ketamine and benzethonium are additive in human lymphoma and neuroblastoma cells and primary rat astrocytes. In the first step of this study, we focused on the apoptosis-inducing and therefore cyto-and neurotoxic effects of S(ϩ)-ketamine and benzethonium in a clinically used ratio (e.g., Ketanest S). We demonstrated that the toxic effects of S(ϩ)-ketamine and benzethonium are at least additive in human lymphoma and neuroblastoma cells. Furthermore, apoptosis was found to be the predominant mode of cell death induced by S(ϩ)-ketamine and benzethonium and their mixture. Thus, in cells of mesenchymal and ectodermal origin the toxicity of S(ϩ)-ketamine was increased by benzethonium.
In a second step of this study, we investigated the dose--toxicity relationship of S(ϩ)-ketamine and benzethonium alone and in combination in neuronal and glial cell cultures to determine whether their toxicities are additive. In both cell types each substance alone displayed an almost identical LD50 but a different slope. Therefore, these substances seem to have similar toxicities in a wide variety of cell types. Finally, these substances displayed additive toxicities in both cell types.
In regard to the toxicity of benzethonium alone in human neuroblastoma cells the sensitivity of our assays (AnnexinV/7AAD and XXT) varied. Although the AnnexinV/7AAD assay could identify apoptosis as the predominant mode of cell death, it has shortages in quantifying the total viability of cells by neglecting cells that already disappeared by lysis. Therefore, we instituted the XTT assay, because it quantifies the total viability of all cells, and used this assay to determine the additivity of the toxicities. Therefore, the quantitative toxicity of benzethonium alone in neuroblastoma cells in the AnnexinV/7AAD assay is presumably underestimated.
Our results are in contrast to those of Errando et al., who demonstrated that only benzethonium is neurotoxic in vivo and that its toxicity is even ameliorated by ketamine. 6 Apart from methodological differences, the authors used a benzethonium concentration about 40 times higher than what we used in our investigation, possibly leading to an overexaggeration of benzethonium's effects. Neuraxial administration of ketamine in humans demands a conscientious risk-benefit analysis. 3, 4, 8 Thus, neuraxial administration of S(ϩ)-ketamine with benzethonium should be even more restricted, because benzethonium increases the toxicity of S(ϩ)-ketamine. Unfortunately, preservative-free S(ϩ)-ketamine solutions have to be stored in a cool environment (4°C) and used at room temperature within 12 hours, which limits their application in pain medicine. Although benzethonium-containing ketamine has been administered epidurally without neurological sequela, 9 the additive toxicity that we demonstrated demands caution when administering benzethonium-containing ketamine solutions epidurally.
We demonstrated that benzethonium and S(ϩ)-ketamine display additive toxicity in neuronal and glial cell cultures. Surely these data cannot be extrapolated to the clinical situation. But because clinical data on the safety of this drug combination are lacking, epidural administration of these drugs should be restricted.
